Designed to target skin cancer, the implantable vaccine opens a door to treating many cancers and inflammatory diseases
A cross-disciplinary team of scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.
The effort is the fruit of a new model of translational research being pursued at the Wyss Institute for Biologically Inspired Engineering at Harvard University that integrates the latest cancer research with bioinspired technology development. It was led by Wyss Core Faculty member David J. Mooney, Ph.D., who is also the Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences (SEAS), and Wyss Institute Associate Faculty member Glenn Dranoff, M.D., who is co-leader of Dana-Farber Cancer Institute’s Cancer Vaccine Center.
Most therapeutic cancer vaccines available today require doctors to first remove the patient’s immune cells from the body, then reprogram them and reintroduce them back into the body. The new approach, which was first reported to eliminate tumors in mice in Science Translational Medicine in 2009, the year the Wyss Institute was launched, instead uses a small disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. The sponge is implanted under the skin, and is designed to recruit and reprogram a patient’s own immune cells “on site,” instructing them to travel through the body, home in on cancer cells, then kill them.
The technology was initially designed to target cancerous melanoma in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine — mice that would have otherwise died from melanoma within about 25 days — showed complete tumor regression.
“Our vaccine was made possible by combining a wide range of biomedical expertise that thrives in Boston and Cambridge,” said Mooney, who specializes in the design of biomaterials for tissue engineering and drug delivery. “It reflects the bioinspired engineering savvy and technology development focus of engineers and scientists at the Wyss Institute and Harvard SEAS, as well as the immunological and clinical expertise of the researchers and clinicians at Dana-Farber and Harvard Medical School.”
“This is expected to be the first of many new innovative therapies made possible by the Wyss Institute’s collaborative model of translational research that will enter human clinical trials,” said Wyss Founding Director Don Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and a Professor of Bioengineering at Harvard SEAS. “It validates our approach, which strives to move technologies into the clinical space much faster than would be possible in a traditional academic environment. It’s enormously gratifying to see one of our first technologies take this giant leap forward.”
The Wyss Institute comprises a consortium of researchers, engineers, clinicians, and staff with industrial and business development experience from the Wyss Institute and nine other collaborating institutions in Greater Boston.
“It is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,” said Dranoff, who is also a Professor of Medicine at Harvard Medical School, and Leader of the Dana-Farber/Harvard Cancer Center Program in Cancer Immunology. “We’re beyond thrilled with the momentum, and excited about its potential.”
The Latest on: Cancer Vaccine
- New cervical cancer test could prevent one in four cases — and experts reckon the disease could be wiped outon January 19, 2020 at 5:33 pm
A NEW cervical cancer test could prevent one in four cases — and experts reckon the disease could be wiped out. Scientists believe the new screening method, coupled with vaccines for children, could ...
- Cervical cancer could be eliminated in England, experts sayon January 19, 2020 at 4:01 pm
By taking the action to click anywhere on this page, or by clicking the “Continue to Site” button, you agree to allow us and various third parties to store and access cookies on your device for MSN ...
- Cervical cancer ‘could be eliminated’ thanks to vaccine and better screeningon January 19, 2020 at 3:04 pm
There are 2,500 new cases of cervical cancer in England every year. A quarter of these could be prevented with the new method of testing. Alongside the new screening, all 12 and 13-year-olds in school ...
- Breast Cancer Survivors May Suffer Negative Side Effects From Acid Reflux Drugson January 18, 2020 at 12:09 am
Acid reflux medicines prescribed to breast cancer patients may have side effects like poorer memory and concentration.
- VBI Vaccines Is Back In Game For 2020on January 17, 2020 at 10:04 am
The company is also studying VBI-2501 as the Zika virus prophylactic vaccine in the pre-clinical stage. VBI Vaccines is also working on cancer vaccines. The company is studying the VBI-1901 vaccine ...
- Global Neoantigen Cancer Vaccine Market is Projected to Reach $1826.1 Million by End of the Forecast Period, 2030 - ResearchAndMarkets.comon January 16, 2020 at 12:44 am
The "Global Neoantigen Cancer Vaccine Market : Focus on Application, Approach, Type, Line of Therapy, Treatment Strategy, Country Data (15 Countries),and ...
- How Moderna is using Amazon cloud to produce personalized cancer vaccineson January 15, 2020 at 9:03 pm
Moderna CEO Stephane Bancel said the biotech company is using the "software of life" to develop treatments for diseases, including one that can be a $5 billion opportunity.
- Avidea Technologies Utilizes GenScript's Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccineon January 15, 2020 at 3:30 am
/PRNewswire/ -- GenScript, a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a ...
- Global Neoantigen Cancer Vaccine Market Study, 2023-2030: Projecting a CAGR of 34.69%; Generating Revenues of $227.1M in 2023 and $1.82B in 2030on January 14, 2020 at 4:08 pm
The "Global Neoantigen Cancer Vaccine Market : Focus on Application, Approach, Type, Line of Therapy, Treatment Strategy, Country Data (15 Countries),and Competitive Landscape - Analysis and Forecast, ...
- Flu vaccines may shrink tumors and boost cancer treatmenton January 11, 2020 at 3:06 am
They found that this "vaccine" turned tumors from cold to hot by increasing the concentration of dendritic cells in the tumors. These cells can stimulate an immune response, and indeed, they led to an ...
via Google News and Bing News